Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma

Marko Oydanich; Elizabeth H Roll; Siri Uppuluri; Albert S Khouri

doi:10.1016/j.jcjo.2023.05.009

Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma

Can J Ophthalmol. 2023 Jun 5:S0008-4182(23)00168-0. doi: 10.1016/j.jcjo.2023.05.009. Online ahead of print.

Authors

Marko Oydanich¹, Elizabeth H Roll¹, Siri Uppuluri¹, Albert S Khouri²

Affiliations

¹ Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, NJ.
² Institute of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Newark, NJ. Electronic address: khourias@njms.rutgers.edu.

PMID: 37290487
DOI: 10.1016/j.jcjo.2023.05.009

Abstract

Objective: To determine the effectiveness of netarsudil, 0.02% in lowering intraocular pressure (IOP) in patients with secondary forms of glaucoma.

Methods: A total of 77 patients (98 eyes) with either primary open-angle glaucoma (POAG) or secondary glaucoma were reviewed retrospectively over the course of 1 year after starting netarsudil. The secondary glaucoma group was comprised of patients with uveitic, pseudoexfoliative, neovascular, congenital, and other forms of secondary glaucoma. Patient IOP measurements were collected at baseline and at 1-, 3-, 6-, and 12-month intervals. Two sample t tests and 1-way analysis of variance were used to determine differences in IOP reductions following netarsudil treatment.

Results: Patients with POAG or secondary glaucomas were matched for age (mean ± SD: 69.1 ± 16.0 years vs. 64.5 ± 21.2 years; p = 0.30). Both the POAG and secondary glaucoma patients exhibited significant decreases in IOP at each time point (1, 3, 6, and 12 months) when compared with baseline (p < 0.05). Both groups showed similar overall decreases in IOP from baseline after 1 year of treatment (6.0 ± 4.5 mm Hg vs. 6.6 ± 8.4 mm Hg; p = 0.70). Forty-sex percent of POAG patients achieved an IOP of <14 mm Hg compared with 17% of secondary glaucoma patients. Among the secondary glaucoma subtypes, netarsudil was found to be most effective for treating uveitic glaucoma, showing a decrease in IOP of 9.5 mm Hg after 12 months (p = 0.02).

Conclusion: Netarsudil is effective in lowering IOP in patients with certain forms of secondary glaucoma and should be considered for IOP management in those with uveitic glaucoma.